Improve polymorph screening with enhanced crystallisation control

Allows a range of solvents and multiple actives to be evaporated at the same slow rate

The eXalt is suitable for labs that perform a range of tasks

Genevac's eXalt non-destructive evaporation technology has been developed with partners in the field of pharmaceutical small molecule crystallisation.

eXalt is suitable for labs that perform tasks including first-time crystallisation of amorphous forms, recrystallisation of samples which have only a few known forms, removing a hydrate, solvent screening studies to find the most suitable conditions to take forward in development, high throughput co-crystallisation screens and studies to confirm stable isoforms.

A range of solvents and multiple actives can be evaporated all at the same slow rate

The product enables a wide range of solvents and multiple actives to be evaporated all at the same slow rate, and under the same conditions, giving the user unprecedented control of the crystallisation process. This is achieved using a special holder which can be configured to slow the evaporation rate for each solvent, i.e. the more volatile solvents are impeded more, and some solvents such as water, need no restriction. The holder is then placed in the controlled conditions of a Genevac HT Series Evaporator which cycles the pressure over the samples to create a draw, achieving controlled, even evaporation.

eXalt holders can accept up to 24 different samples, and 4, 8 or 12 holders can be placed in the evaporator, depending on size.

Companies